ALK-POSITIVE BONE CANCER

Clinical trials for ALK-POSITIVE BONE CANCER explained in plain language.

Never miss a new study

Get alerted when new ALK-POSITIVE BONE CANCER trials appear

Sign up with your email to follow new studies for ALK-POSITIVE BONE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New hope for rare bone cancer: targeted pills aim to shrink tumors

Disease control Not yet recruiting

This early-stage trial tests two targeted drugs, crizotinib and alectinib, in people with a rare bone cancer that has a specific genetic change (truncated ALK). The goal is to see if these drugs can shrink or control the cancer. The study enrolls about 10 adults whose cancer has …

Matched conditions: ALK-POSITIVE BONE CANCER

Phase: PHASE1, PHASE2 • Sponsor: China Medical University Hospital • Aim: Disease control

Last updated May 05, 2026 11:54 UTC

ALK-POSITIVE BONE CANCER

Get alerted when new ALK-POSITIVE BONE CANCER trials appear

New hope for rare bone cancer: targeted pills aim to shrink tumors